3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
175
Neoplasm Metastasis
19
Breast Neoplasms
19
Prostatic Neoplasms, Castration-Resistant
17
Neoplasms
16
Metastatic Castration Resistant Prostate Cancer
8
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Triple Negative Breast Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Melanoma
4
Colorectal Neoplasms
4
Castration-resistant Prostate Cancer
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Prostate Adenocarcinoma
3
Ovarian Neoplasms
3
Carcinoma, Hepatocellular
3
mCRPC
2
Uterine Cervical Neoplasms
2
Recurrence
2
Prostatic Diseases
2
Metastatic Hormone Sensitive Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
2
Interventions
Sunitinib
3
avelumab
2
Nutrition Assessment
2
Axitinib
2
trifluridine tipiracil drug combination
1
trebananib
1
spartalizumab
1
pembrolizumab
1
palbociclib
1
etelcalcetide hydrochloride
1
enzalutamide
1
cabozantinib
1
bicalutamide
1
atezolizumab
1
aldesleukin
1
Valsartan
1
VMBP protocol
1
Stents
1
Sorafenib
1
Sodium Bicarbonate
1
Resistance Training
1
Receptors, Androgen
1
Plasma Exchange
1
Pharmaceutical Preparations
1
Paclitaxel
1
Oxaliplatin
1
Nivolumab
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Lysine Acetyltransferase 5
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Kidney Diseases
×
enzalutamide
×
Clear all
NCT05700903
2026-03-02
ARCH
University of Colorado, Denver
Phase 4
Completed
10 enrolled